Amedisys (AMED)
(Delayed Data from NSDQ)
$94.55 USD
+0.47 (0.50%)
Updated May 9, 2024 04:00 PM ET
After-Market: $94.48 -0.07 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Price, Consensus and EPS Surprise
AMED 94.55 +0.47(0.50%)
Will AMED be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AMED based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMED
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Rise
Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics
AMED: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amedisys (AMED) Q1 Earnings and Revenues Surpass Estimates
Premium Growth Propels Humana (HUM) to Easy Q1 Earnings Beat
Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Other News for AMED
AMED Crosses Above Key Moving Average Level
Amedisys gains amid report of sweetened divestiture offer in UnitedHealth deal
What's Driving Select Medical Holdings Corp's Surprising 16% Stock Rally?
Analysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Gilead Sciences (GILD)
Truist Financial Reaffirms Their Hold Rating on Amedisys (AMED)